Research & Development
Scientific Overview
Scientific Presentations
Scientific Advisory Board
Clinical Studies
Clinical Trial Participation
Clinical Trial Sites
Pre-Clinical
Research
Product Pipeline
Scientific Reports
 |
||||||||||
 |
 |
|||||||||
 |
 |
 |
 |
 |
||||||
 |
 |
|||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
Kidney Tissue | |||||||||
|
3 Million Patients Suffer From Hypertensive Renal Disease Hypertensive renal disease results from the blockage of arteries supplying the kidneys. In animal models of ischemic kidney disease, FGF-1141 has been shown to stimulate new blood flow, resulting in an increased perfusion of the kidneys, and a decrease in the ischemic injury. There is no therapy at present that will reverse this disease. However, since the kidney is a complex organ, CVBT will take a cautious approach to treating renal disease.
Use of
this site constitutes agreement to our Terms and Conditions Some content on this site requires the free Adobe
Reader. | ||||||||||
 |
||||||||||
 |
|
|
|
|
|
|
|
|
|
|
2/24/2009
CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial
1/8/2009
CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial
12/11/2008
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
11/25/2008
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease